Slides
Page 1
Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com FDA Approved I Commercially Proven I Platform Enabled Botanix Pharmaceuticals Limited · ASX:BOT · botanixpharma.com Investor Presentation Q4 FY26 27 July 2026
Page 2
Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com 1.Summary information The following notice and disclaimer applies to this investor presentation (“Presentation”) and you are therefore advised to read this carefully before reading or making any other use of this Presentation or any information contained in this Presentation. By accepting this Presentation, you represent and warrant that you are entitled to receive this Presentation inaccordance with the restrictions, and agree to be bound by the limitations, contained within it. This Presentation is dated 27 July 2026 and has been prepared by Botanix Pharmaceuticals Limited(ABN 70 009 109 755) (“Botanix” or “the Company”). The information contained in this Presentation is of a general nature and does not purport to be complete nor does it containall the information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information contained in this Presentation is a summary only and should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (“ASX”), which are available at www.asx.com.au. 2.Not an offerEach recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of the Company and the impact that different future outcomes might have on the Company and form their own views as to what information is relevant to such decisions and made their own investigations in relation to any additional information. This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire shares and does not and will not form any part of any contract for the acquisition of shares. Information in this Presentation is not intended to be relied upon as advice to investors or potential investors and has been prepared without taking account of any person’s individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. The Company is not licensed to provide financial product advice in respect of its securities. 3.Not investment advice This Presentation does not constitute or contain an offer, invitation, solicitation or recommendation to subscribe for, acquire or sale of any securities in Botanix, or any other financial products or securities, in any place or jurisdiction. This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law or any other law and will not be lodged with the Australian Securities and Investments Commission. Persons who come into possession of this Presentation should observe any such restrictions as any non-compliance could contravene applicable securities laws.4.Industry data Certain market and industry data used in connection with or referenced in this Presentation has been obtained from public filings, research, surveys or studies made or conducted by third parties, including as published in industry-specific or generalpublications. Neither Botanix nor its advisers, or their respective representatives, have independently verified any such market or industry data. 5.Financial dataAll dollar values are in Australian dollars ($ or A$) unless otherwise stated. Amounts, totals and change percentages are calculated on whole numbers and not the rounded amounts presented. USA Headquarters:Suite 202, 2390 E Camelback Road Phoenix AZ 85016Corporate Office: Level 23, Tower 5, Collins Square727 Collins Street, Melbourne VIC 3008 6.Forward-looking statements and forecasts This Presentation contains certain “forward-looking statements” and comments about future matters. Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of Sofdra® and the market for Sofdra®. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements. Any such statements, opinions and estimates in this Presentation speak only as of the date hereof, are preliminary views and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Any such forward-looking statements are also based on assumptions and contingencies which are subject to change and which may ultimately prove to be materially incorrect, as are statements about market and industry trends, which are based on interpretations of current market conditions. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements (particularly in light of the current economic climate and significant volatility). The forward-looking statements in this Presentation are not guarantees or predictions of future performance and may involve significant elements of subjective judgment, assumptions as to future events that may not be correct, known and unknown risks, uncertainties and other factors, many of which are outside the control of Botanix. Except as required by law or regulation, Botanix undertakes no obligation to finalise, check, supplement, revise or update forward-looking statements or to publish prospective financial information in the future, regardless of whether new information, future events or results or other factors affect the information contained in this Presentation. Certain data used in this Presentation have may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. It should be read in conjunction with Botanix’s otherperiodic and continuous disclosure announcements lodged with the ASX, which are available at www.asx.com.au or at https://botanixpharma.com/invest/ 7.DisclaimerThe Company and its related bodies corporate and each of their respective directors, agents, officers, employees and advisersexpressly disclaim, to the maximum extent permitted by law, all liabilities (however caused, including negligence) in respectof, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this Presentation does not constitute, and shall not be reliedupon as, a promise, representation, warranty or guarantee as to the past, present or future performance of the Company.8.This Presentation is authorised for release by the Board. 2 Important Notices & Disclaimer
Page 3
Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Corporate snapshot >30 successful dermatology product launches VINCE IPPOLITO Executive Chairman HOWIE MCKIBBON Chief Executive Officer CAREY HERBERT Chief Legal & Compliance Officer CHRIS LESOVITZ Chief Financial Officer, U.S. PAUL SEABACK Chief Operating Officer MARTINA CARTWRIGHT VP, Medical Affairs Botanix team has expertise acquiring & launching dermatology drugs that become market leaders LEISHA MARTIN SVP, Quality, Regulatory & PV 3
Page 4
Botanix Pharmaceuticals Limited Sofdra®FDA-approved, on-marketPlatformBuilt, productive, scalableOpportunityBolt-on dermatology assets●Large underserved market of 10 million patients●Prescribers are highly responsive to promotion●Overwhelmingly high physician and patient satisfaction●Broad patent protection to 2040 ●Sofdra®prescriptions shipped grew 25% to 33,358 in Q4 FY26 vs Q3 FY26 ●Improves gross to net yield●Fill rate 2.5 times industry standard●High rate of fully reimbursed prescriptions●High physician and patient satisfaction confirmed by market research ●Distribution efficiencies and above industry fill rates increase net revenue●Validated platform is scalable to add new products at a low incremental investment●Highly successful sales professionals have capacity to sell products alongside Sofdra® Three key pillars drive Botanix near-and long-term value Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com 4
Page 5
30.237.938.0 46.7 020406080100120140160180 Q1 FY26Q2 FY26Q3 FY26Q4 FY26 Key accomplishments in the trailing 12 months —Botanix maintains momentum Millions Thousands $152.8million1 Cumulative Gross Revenue 7.1 9.1 6.9 10.1 05101520253035 Q1 FY26Q2 FY26Q3 FY26Q4 FY26 $33.2million1 Cumulative Net Revenue Millions Cumulative Total Prescriptions 20.425.3 26.7 33.4 020406080100120 Q1 FY26Q2 FY26Q3 FY26Q4 FY26 105.8kshipped1 5 Proven Growth Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com 1. Annual figures are unaudited. 5
Page 6
Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Sofdra® Total Prescriptions Shipped 20,401 25,351 26,684 33,358 Q1 FY26Q2 FY26Q3 FY26Q4 FY26 Shipments grew 25% to 33,358 in Q4 FY26 vs Q3 FY26June set an all-time high for Sofdrawith TRx shipments of 12,895Sales momentum is expected to continueIn a new survey conducted by Botanix in May: 100% of recently surveyed HCPs expected to increase or maintain Sofdraprescribing in the following 6 months; none expected to reduce Sofdraprescribing. Total Prescriptions Shipped 6
Page 7
Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Net revenue resumed growth following annual deductible reset in Q3 Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Sofdra® Net Revenue $7.1$9.1$6.9 $10.1 Q1 FY26Q2 FY26Q3 FY26Q4 FY26 Q3/Q4Annual deductible reset occurs in January, when US health insurance resets, requiring patients to pay all medical costs until deductible is metMAY→Reimbursement rates normalize after patients meet their deductibles, typically from May forward Sofdra®Net Revenue in Millions 7
Page 8
Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com GTN improved from 18% in Q3 FY26 to 22% in Q4 FY26 GTN is expected to continue its upward trajectory into Q1 FY27 Gross to Net Yield 23%24% 18%22% Q1 FY26Q2 FY26Q3 FY26Q4 FY26 Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Gross-to-net (GTN) yield improved to 22% following annual deductible reset in Q3 8
Page 9
Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Quarterly PerformanceQ4 FY26 delivered solid capital and inventory positions to support growth Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Q4 CASH & CASH EQUIVALENTS $36.6mVersus Cash and cash equivalents of $22.1m in Q3 ~$31.3mINVENTORY BALANCECompared with $34.5m in Q3Botanix has an adequate supply of API for its interim growth needs $(10.6m)OPERATING CASH OUTFLOWOperating net cash outflows decreased 54% versus $23.3m ($13.6m excluding API purchase) in Q3 9
Page 10
30 Sep 2531 Dec 2531 Mar 2630 Jun 26Cash flows from operating activitiesReceipts from Royalties504435216193 Receipts from product sales, net of fees8,27111,89011,25213,416 Payments for gross to net deductions from product sales(2,666)(5,051)(5,500)(6,421)Payments for:a) Product manufacturing(2,171)(2,705)(11,045)(1,194)b) Operating costs(10,241)(14,665)(12,780)(11,473)c) Staff Costs (3,471)(4,588)(2,606)(2,722)d) G&A (1,873)(1,454)(1,701)(1,701)e) Royalty payments(495)(598)(551)(453)Interest received402303178234 Interest paid (531)(791)(759)(499)Other non-recurring payment(844)Net cash from / (used in) operating activities$(13,115)$(17,224)$(23,296)($10,620)Cash flows from investing activitiesCash flows from loans to other entities(436)Net cash from / (used in) investing activities(436)Cash flows from financing activitiesProceeds from issues of equity securities14,88030,120Proceeds from exercise of options21Transaction costs related to issues of equity securities(818)(2,372)Proceeds from borrowingsDebt repayments (2,816)Transaction costs related to loans and borrowings(2,331)(39)Other (Payment for right-of-use asset)(108)(136)(157)(127)Net cash from / (used in) financing activities$(2,418)$(175)$13,905$24,805 Net increase / (decrease) in cash and cash equivalents for the periodCash and cash equivalents at beginning of period$64,888$49,246$31,498$22,100 Net cash from / (used in) operating activities(13,115)(17,224)(23,296)(10,620)Net cash from / (used in) investing activities(436)Net cash from / (used in) financing activities(2,418)(175)13,90524,805 Effect of movement in exchange rate on cash(109)87(7)346 Cash and cash equivalents at end of period$49,246$31,498$22,100$36,631 % Change Q3 FY26 to Q4 FY26 vReceipts from product sales increased 19% to $13.4m, reflecting stronger sales volumes and improved gross receipts versus the prior quarter.vProduct manufacturing costsdecreased 89% to $1.2m, as the prior quarter included inventory/API purchases while Q4 reflected normal production requirements.vOperating costsdecreased 10% to $11.5m, driven by lower operating expenditures across the business.vStaff costs increased nominally by 4% to $2.7m, primarily reflecting timing of payroll and employee-related costs.vG&A costs remained consistent with the prior quarter.vNet cash outflow from operating activities decreased 54% to $10.6m driven by higher sales receipts and the absence of significant inventory/API purchases incurred in the prior quarter. Improved by $12.6m (54%) to $10.6m, reflecting stronger sales and normalised manufacturing spend Operating cash outflow 10
Page 11
Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Driving Sustainable GrowthDriving growth through efficient resource allocation and cash flow discipline Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Cash Flow Optimisation•Operating cash outflow improved significantly to $10.6 million in Q4 FY26, from $23.3 million in Q3 FY26•Driven by 19% growth in product sales receipts•Delayed next ~$9.7m API purchase until December 2027 while maintaining sufficient inventory for growth1 Efficient Resource Allocation•Botanix is completing a sales force sizing and alignment initiative•90% of prescriptions are generated by 39 of 50 sales territories•The most valuable physician targets will be reallocated from 11 unprofitable territories to the 39 high-performers to maintain 94% coverage and continue growth•Reducing the sales force size by 11 will lower operating costs by ~12% beginning 31 July 2026 1.BotanixPharmaceuticals,‘SuccessfulrenegotiationofAPIsupplyagreement’(ASXAnnouncement,29/03/2026) 11
Page 12
Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com •Continue to grow Sofdra® and increase momentum•Improve cash flow performance and enhance working capital management•Optimise resource allocation and sales force alignment Raise Operational Execution & Capital Efficiency •Pursue strategic acquisition opportunities to accelerate / improve value creation •Engage with the significant inbound interest, including relating to potential licensing and acquisitions Explore Strategic Acquisition Activity Focused on shareholder value Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Botanix is strongly focused on unlocking and enhancing shareholder value •Strengthen the intellectual property estate of Botanix•Onboard alternate API supplier to reduce COGS by 25% –40%1 •Support additional products and future growth with the Botanix Fulfilment Platform Prepare to Execute Licensing Opportunities 1.BotanixPharmaceuticals,‘Botanixreachestermsheetagreementwith2ndAPIsupplier’(ASXAnnouncement,15/04/2026) 12
Page 13
Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Sofdra® Botanix Pharmaceuticals Limited · ASX:BOT · botanixpharma.com Targeting a US market spanning10 million Americans with primary axillary hyperhidrosis.
Page 14
Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Sources: 1. Doolittle J, et al. Hyperhidrosis: an update on prevalence and severity in the United States.Arch Dermatol Res. 2016;308:743-749.; 2. Peretto I, Petrillo P, Imbimbo BP. Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists. Med Res Rev. 2009 Nov;29(6):867-902.doi: 10.1002/med.20158. A first-of-its-kind solution for primary axillary hyperhidrosis Hyperhidrosis is a medical condition characterisedby excessive sweating beyond what is needed to maintain normal body temperature.1 First and only new chemical entityFDA approved for primary axillary hyperhidrosis (excessive underarm sweating)Safe and effective treatment option, for adults andpediatric patients ≥9 Commercial launchcommenced February 2025Strong physician adoption andpatient satisfaction Broad patent protection through2040 About Sofdra® (sofpironium) Reduces sweat at its source by selectively binding to M3 receptors to block acetylcholine2 Proprietary drug delivery system through innovative applicator design that limits unwanted drug contact with hands. Applicator 14
Page 15
Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Sofdra® patent protection into 2040 NCE exclusivity06/2029 Method-of-Use Patents & Drug Product03–05/2034Gel Formulation and Method-of-Use 07/2037Drug-Device (Applicator), if issued05/2039Drug Substance Crystalline Forms, Drug Product and Method-of-Use 05/2040202420262028203020322034203620382040 30-Month Stay12/2031 Strong IP supports an extended commercialisation runway and expands strategic partnering opportunitiesIn July:Botanix received an Intention to Grant for a European patent application and a Notice of Allowance for a US patent application.1,2Alongside patents already in place, these developments strengthen the company's intellectual property estate around Sofdraand enhance its long-term value proposition into 2040. 1.BotanixPharmaceuticals,‘IntentiontograntaEuropeanpatentonSofdraapplicator’(ASXAnnouncement,06/07/2026)2.BotanixPharmaceuticals,‘NoticeofAllowanceforUSPatentonSofdradrugsubstance’(ASXAnnouncement,12/07/2026) 15
Page 16
Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Potential 25% –40% reduction in cost of goods sold and increased gross profitAlternate API supplier Botanix has agreed to terms with PPL Pharma Solutions Riverview LLC (“Piramal”) for a proposed manufacturing and supply arrangement between Botanix and Piramal under which Piramal will commence certain development services and serve as an alternate commercial supplier of Sofpironium Bromide, the active pharmaceutical ingredient (API) in Sofdra.1 vTechnical transfer is underwayvParties to negotiate definitive commercial API supply agreement vAPI is anticipated to be available from Piramal in 2028vBenefits realised progressively during 2028 API supply transitionvDe-risk the Botanix supply chainvUS manufacturing site is favourable for US tariff management 1.BotanixPharmaceuticals,‘Botanixreachestermsheetagreementwith2ndAPIsupplier’(ASXAnnouncement,15/04/2026) 16
Page 17
Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Primed for additional products at a low incremental cost PHARMACY PATIENT WHOLESALER PRESCRIBER CO-PAY REBATE BOTANIX Consigned ProductMCO REIMBURSEMENT/PATIENT RESPONSIBILITY DISCOUNT MCO I’ve never used a specialty pharmacy that has been as seamlessas SendRx. I put a prescription in on Friday afternoonand the patient had their medication by Saturday morning.–Dermatologist response1 Source: 1. Data on file Botanix Pharmaceuticals survey April 2025. Supply chain cost savings –bypassing the wholesaler ü High fill and refill rates ü Increase reimbursed Rx ü Seamless fulfillment ü Improve gross-to-net yield ü The Botanix Fulfilment Platform 17
Page 18
Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Catalysts to drive Botanix performance Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com Deliver continued Sofdra®growth Add new products to platform to accelerate growth & profitability with low investment Decrease COGS 25% –40% by onboarding alternate API supplier Expand Sofdralicensing to other regions for increased revenue Long IP runway to 2040 elevates Botanix value proposition for mergers and acquisitions 18
Page 19
Botanix Pharmaceuticals Limited FDA Approved | Commercially Proven | Platform Enabled INVESTOR RELATIONS CONTACT: wr@janemorganmanagement.com.au Botanix Pharmaceuticals Limited ASX:BOT botanixpharma.com Botanix Pharmaceuticals Limited · ASX:BOT · Investor Presentation July 2026 · botanixpharma.com19